FDA-Approved Medications for Both MRSA and MSSA
Linezolid and daptomycin are the two agents FDA-approved for treatment of both methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible Staphylococcus aureus (MSSA) infections.
Primary Recommendations
Based on IDSA guidelines, these two agents have distinct FDA approvals and clinical applications 1:
Linezolid
- FDA-approved for: Skin and soft tissue infections (SSTI) and pneumonia caused by both MRSA and MSSA
- Dosing: 600 mg PO/IV twice daily (adults); 10 mg/kg/dose every 8 hours in children <12 years (not to exceed 600 mg/dose)
- Evidence level: AI/AII across multiple infection types 1
- Route flexibility: Available in both oral and intravenous formulations, providing treatment continuity
Daptomycin
- FDA-approved for: Complicated SSTI (4 mg/kg/dose IV daily) and bacteremia/right-sided endocarditis (6 mg/kg/dose IV daily) caused by both MRSA and MSSA
- Evidence level: AI for complicated SSTI and bacteremia 1
- Critical limitation: Cannot be used for pneumonia - daptomycin is inactivated by pulmonary surfactant 2
Clinical Context and Supporting Evidence
Recent research confirms daptomycin's rapid bactericidal activity and effectiveness as an alternative to vancomycin for MRSA or MSSA bacteremia and right-sided endocarditis 3. A 2014 review reinforces that daptomycin should be considered in patients with MRSA bacteremia and right-sided endocarditis as well as complicated SSSIs 2.
Important Caveats
Emerging resistance concerns: Recent 2026 data shows alarming resistance rates to linezolid (41% non-susceptibility) and concerning patterns with other agents, though daptomycin maintains 96.3% susceptibility 4. Multiple recent studies confirm daptomycin, linezolid, and vancomycin remain highly effective, with near-complete susceptibility in clinical isolates 5.
Other agents with activity but different approval status:
- Vancomycin: While effective against both MRSA and MSSA, it is primarily indicated for MRSA (not specifically FDA-approved for MSSA when better alternatives exist)
- Clindamycin: Has activity against both but faces resistance issues and is not universally approved for all MRSA infections
- Telavancin: FDA-approved for complicated SSTI but less commonly used 1
Practical Application Algorithm
For complicated SSTI:
- Either linezolid (600 mg PO/IV BID) OR daptomycin (4 mg/kg IV daily) 1
For bacteremia/endocarditis:
- Daptomycin (6 mg/kg IV daily) is preferred 1
- Linezolid is an alternative but with lower evidence level
For pneumonia:
- Linezolid (600 mg PO/IV BID) - daptomycin is contraindicated 1
Duration: Typically 7-14 days for SSTI, individualized for bacteremia/endocarditis based on clinical response and source control 1